Chronic Lymphocytic Leukemia Clinical Trial

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Summary

The purpose of this study is to evaluate the safety and preliminary efficacy of BMS-986403 in participants with relapsed and/or refractory leukemia-cll/" >chronic lymphocytic leukemia (R/R CLL) or small lymphocytic lymphoma (SLL).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and high-risk features must have failed at least 2 lines of prior therapy and participants with CLL or SLL and standard risk features must have failed at least 3 lines of prior therapy
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
Either currently has central vascular access or is a candidate to receive central vascular access or peripheral vascular access for leukapheresis procedure
Has recovery to Grade ≤ 1 or baseline of any non-hematologic toxicities due to previous therapy, except alopecia (any Grade acceptable) and peripheral neuropathy (Grade ≤ 2 acceptable)

Exclusion Criteria:

Any condition, including active or uncontrolled infection, or the presence of laboratory abnormalities, that places the subject at unacceptable risk if they were to participate in the study
Systemic fungal, bacterial, viral, or other infection that is not controlled
Active autoimmune disease requiring immunosuppressive therapy
Progressive deep vein thrombosis or pulmonary embolism requiring treatment, but not yet on a stable anticoagulation regimen

Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 1

Estimated Enrollment:

5

Study ID:

NCT05244070

Recruitment Status:

Terminated

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

Local Institution - 0005
Birmingham Alabama, 35249, United States
Local Institution - 0016
Duarte California, 91010, United States
Local Institution - 0007
Boston Massachusetts, 02114, United States
Local Institution - 0026
Hackensack New Jersey, 07601, United States
Local Institution - 0009
Columbus Ohio, 43210, United States
Local Institution - 0002
Seattle Washington, 98109, United States
Local Institution - 0024
Barcelona , 08035, Spain
Local Institution
Madrid , 28040, Spain
Local Institution
Salamanca , 37007, Spain

How clear is this clinincal trial information?

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 1

Estimated Enrollment:

5

Study ID:

NCT05244070

Recruitment Status:

Terminated

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.